Mowat A M, Donachie A M, Reid G, Jarrett O
Department of Immunology, Western Infirmary, Glasgow, U.K.
Immunology. 1991 Mar;72(3):317-22.
Induction of all forms of protective immunity by oral immunization with subunit vaccines is an ideal goal for the development of novel vaccines, but creates several theoretical problems from the point of view of antigen processing mechanisms. We show here that incorporation of the protein antigen ovalbumin (OVA) in lipophilic immune-stimulating complexes (ISCOMS) induces very strong primary immune responses in mice and requires very small amounts of antigen. OVA ISCOMS were particularly efficient at stimulating T-cell-mediated immunity in vivo, including delayed-type hypersensitivity (DTH) and potent class I major histocompatibility complex (MHC)-restricted cytotoxic T-cell responses. Furthermore, unlike native protein, OVA in ISCOMS was immunogenic when given orally. Thus, ISCOMS seem to allow protein to enter both the endogenous and exogenous pathways of antigen processing and overcome the usual induction of tolerance after feeding antigen. ISCOMS could provide potentially useful adjuvants for the development of oral subunit vaccines.
用亚单位疫苗进行口服免疫诱导各种形式的保护性免疫是新型疫苗开发的理想目标,但从抗原加工机制的角度来看会产生几个理论问题。我们在此表明,将蛋白质抗原卵清蛋白(OVA)掺入亲脂性免疫刺激复合物(ISCOMS)中可在小鼠中诱导非常强烈的初次免疫反应,并且所需抗原量极少。OVA ISCOMS在体内刺激T细胞介导的免疫方面特别有效,包括迟发型超敏反应(DTH)和强大的I类主要组织相容性复合体(MHC)限制性细胞毒性T细胞反应。此外,与天然蛋白质不同,ISCOMS中的OVA口服时具有免疫原性。因此,ISCOMS似乎能使蛋白质进入抗原加工的内源性和外源性途径,并克服喂食抗原后通常诱导的耐受性。ISCOMS可为口服亚单位疫苗的开发提供潜在有用的佐剂。